Welcome to our dedicated page for Longevity Health news (Ticker: XAGE), a resource for investors and traders seeking the latest updates and insights on Longevity Health stock.
Longevity Health Holdings, Inc. (XAGE) is a company focused on human longevity and healthy aging, with an emphasis on regenerative bio-aesthetics, diagnostics, and nutrition. Its news flow provides insight into how the business evolves across product development, strategic transactions, and capital markets activity.
Company announcements have highlighted a portfolio that includes regenerative technologies for skin and hair health, such as Carmell Secretome™ and Elevai Exosomes™, as well as a strategy to connect these products with diagnostic testing and contemplated nutrition offerings. News items describe merger agreements, including a proposed combination with 20/20 BioLabs, Inc., a developer of laboratory tests for early detection and proactive management of chronic disease risk, and a later merger agreement with True Health Inc. (THPlasma), a plasma collection business, which was subsequently terminated when closing conditions were not met by the agreed deadline.
Investors following XAGE news can review updates on reverse stock split actions, Nasdaq listing decisions, at-the-market equity financings, and detailed merger terms and amendments disclosed through press releases and related SEC filings. Coverage also includes business updates on new product launches, diagnostic test initiatives, and cross-marketing plans between Longevity’s bio-aesthetic offerings and partner diagnostic platforms.
This news page aggregates these developments so readers can track Longevity’s transaction history, listing status changes, financing steps, and strategic positioning in longevity-focused bio-aesthetics and diagnostics. Regular review of XAGE news can help investors and observers understand how the company’s stated strategy and corporate structure change over time.
Longevity Health Holdings (NASDAQ:XAGE) has announced a definitive merger agreement with THPlasma in an all-stock transaction valued at $59 million plus $20 million in earnouts. The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare.
THPlasma, a profitable plasma collection company, is expanding from 2 centers in FY24 to 5 centers in FY25, with guaranteed sales agreements worth $100 million annually. The company projects FY2025 revenue of $10 million and expects significant growth to $32 million in FY2026.
The combined company will continue trading as XAGE, with THPlasma's George Chi becoming Co-Chairman and CEO. Simultaneously, Longevity announced the termination of its planned 20/20 BioLabs transaction. The merger is expected to close in Q4 2025.
Longevity Health Holdings (NASDAQ: XAGE) has successfully completed an at-the-market (ATM) equity offering, selling 479,621 shares at an average price of $4.08 per share, raising gross proceeds of $1.96 million. The funding is expected to extend the company's cash runway into Q1 FY26, based on FY24 pro forma consolidated sales projections. The financing comes as XAGE prepares for its planned merger with 20/20 while continuing to focus on its longevity products business.
Longevity Health Holdings (NASDAQ: XAGE) announced several key business updates. The company has entered into a merger agreement with 20/20 BioLabs on April 11, 2025, with an S-4 prospectus filed on May 8. Q1 unaudited sales showed growth for both companies: XAGE reported $663,000 (+8% YoY) while 20/20 achieved $562,000 (+15% YoY).
The company completed a 1-for-30 reverse stock split on May 12, 2025. Both companies plan Q2 product launches: XAGE will introduce a medicated cleanser for medical professionals, while 20/20 will launch a blood inflammatory biomarker test. Additionally, 20/20 initiated a pilot program with Giant Food for their OneTest™ multi-cancer test at 9 stores in Maryland and Virginia. XAGE is exploring additional financing options for Q2 2025.
Longevity Health Holdings (NASDAQ: XAGE) has announced a 1-for-30 reverse stock split effective May 12, 2025. The split will reduce outstanding shares from approximately 30.1 million to 1 million. Trading on the split-adjusted basis will begin on the Nasdaq Capital Market on May 14, 2025, under the same ticker symbol "XAGE".
The reverse split was approved by stockholders on March 24, 2025. Fractional shares will be rounded up to the nearest whole share. No stockholder action is required for those holding shares electronically or in street name. Proportional adjustments will be made to outstanding stock options, warrants, and shares under the 2023 Equity Incentive Plan.
Longevity Health Holdings (NASDAQ: XAGE) has announced a merger agreement with 20/20 BioLabs in an all-stock transaction valued at approximately $99 million. The merger is expected to double Longevity's fiscal year 2025 revenue from $3-4 million to $7-8 million, with anticipated operational savings of over $1 million.
20/20 BioLabs operates a CLIA Licensed, CAP Accredited lab and offers OneTest™, a multi-cancer early detection blood test for over a dozen tumor types at under $200. The company has integrated its testing into routine evaluations for firefighters and military veterans, and plans to launch a longevity test in Spring 2025.
Post-merger, the combined company will continue trading under XAGE, with Jonathan Cohen appointed as CEO while Rajiv Shukla remains Chairman. The merger advances Longevity's strategy in diagnostics and synergizes with its bio-aesthetic portfolio under the banner "Healthy Aging, Inside and Out™".